Redoxis AB has signed an agreement with Taconic Biosciences, Inc for service of characterization of cellular composition of Taconic’s humanized immune system mice. This contract covers a recurrent service spanning over three years.
“We are very excited about the collaboration with Taconic, which will beneficially impact Redoxis by adding value and financial stability to our in vitro service platform” says Malin Hultqvist Hopkins, CEO, Redoxis.
For additional information please contact:
Malin Hultqvist Hopkins, CEO Redoxis AB
Kelly Owen Grover, Director of Marketing Communications, Taconic Biosciences INC